Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KRAS G12D
i
Other names:
KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3845
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Related tests:
therascreen® KRAS RGQ PCR Kit (5)
therascreen® KRAS RGQ PCR Kit (5)
Associations
(64)
News
Trials
Search handles
@ACortelliniMD
@APassaroMD
@ArndtVogel
@BenWestphalen
@BenjaminBesseMD
@BijoyTelivala
@DanZhaoMD
@DrEzraCohen
@DrJNaidoo
@DrShubhamPant
@DrSteveMartin
@DucreuxMichel
@FogacciJoao
@IbrahimSahinMD1
@MPishvaian
@PTarantinoMD
@SKamath_MD
@StephenVLiu
@SyedAAhmad5
@VivekSubbiah
@cancerassassin1
@doctorpemm
@dplanchard
@drallysonocean
@drjgauthier
@jonathanloree
@marklewismd
@mihaela_aldea
@ogarrieta
@pashtoonkasi
@weldeiry
@zpyeung
Search handles
@ACortelliniMD
@APassaroMD
@ArndtVogel
@BenWestphalen
@BenjaminBesseMD
@BijoyTelivala
@DanZhaoMD
@DrEzraCohen
@DrJNaidoo
@DrShubhamPant
@DrSteveMartin
@DucreuxMichel
@FogacciJoao
@IbrahimSahinMD1
@MPishvaian
@PTarantinoMD
@SKamath_MD
@StephenVLiu
@SyedAAhmad5
@VivekSubbiah
@cancerassassin1
@doctorpemm
@dplanchard
@drallysonocean
@drjgauthier
@jonathanloree
@marklewismd
@mihaela_aldea
@ogarrieta
@pashtoonkasi
@weldeiry
@zpyeung
Filter by
Latest
8ms
.@LudaBazhenovaMD, of @UCSDHealth, covered treatment and resistance with KRAS G12C inhibitors in NSCLC and highlighted MRTX1133 and RAS(ON), both KRAS G12D inhibitors. Still early stages but potential activity with RAS(ON) inhibitors in KRAS G12C-resistant disease #ILCC #lcsm (@OncLive)
8 months ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D
|
MRTX1133
8ms
Paper published 🤩📄 Impact of KRAS G12D and concurrent mutations on NSCLC outcomes. Go and CHECK IT OUT! 🧬 Read 👉🏻 https://t.co/tKRM2KgL0c Team effort 🤩🫁 👨🏻⚕️@Ecaballep 👩🏽⚕️@YanHernandezP 👩🏻⚕️@maritza_rramos 👨🏻⚕️@AndresFCardonaZ 👨🏻⚕️ @ogarrieta #KRAS #NSCLC #outcome #UFOT #INCan (@UToracica)
8 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12
8ms
Impact of KRAS G12D and concurrent mutations on NSCLC outcomes. Our cohort shows 15.6% mKRAS (32, 32, 14% for G12C, G12D and G12V), G12D is associated with female and a lower smoking rate (pack/year). @incanMX @AndresFCardonaZ @Ecaballep https://t.co/YVgxHYVNAZ (@ogarrieta)
8 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12
10ms
Always a treat to hear @Aiims1742 describe RAS signalling and differences in KRAS mutant alleles in #PancreaticCancer pathogenesis ➡️ integration of transcriptomics to interrogate TME and metabolomics #abstract4020 ✅ Differences certainly in G12D vs G12R (@graokane)
10 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D
10ms
AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P #immunotherapy for patients with high-relapse risk with #KRAS G12D- or G12R-mutated pancreatic and colorectal cancer. @EileenMOReilly #ASCO23 #ASCO2023 #clinicaltrials #news https://t.co/ITEzfo6nRF (@imedverse)
10 months ago
Clinical • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D • KRAS G12
10ms
Neoantigen TCR Cell Therapy in Gastrointestinal Malignancies. Great Talk by James C. Yang, MD from the @NCI_CCR_SB #ASCO23 #CRCSM @OncoAlert TCR from a successful case with TILs in #CRC maybe useful in other patients? TILs targeting KRAS G12D? TP53? (@manjuggm)
10 months ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)
|
KRAS G12D • KRAS G12
10ms
Abstract 2528: AMPLIFY-201, a 1st-in-human safety & efficacy trial of adjuvant ELI-002 immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated #PancreaticCancer & #ColorectalCancer. @EileenMOReilly & @DrShubhamPant 👉🏽 non-mRNA vaccine in adjuvant space. (@Aiims1742)
10 months ago
Clinical • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D • KRAS G12
11ms
40 M, met colon cancer, right sided On Folfox + bev NGS with BRCA2 + KrasG12D mutation No trial available Upon progression Tx? Of Label PARP? FOLFIRI+ Bev/Rami Other? (@BijoyTelivala)
11 months ago
Next-generation sequencing
|
KRAS (KRAS proto-oncogene GTPase) • BRCA2 (Breast cancer 2, early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
|
KRAS mutation • KRAS G12D • KRAS G12
|
5-fluorouracil • irinotecan • leucovorin calcium
11ms
Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer https://t.co/soxmYBMnuM (@VivekSubbiah)
11 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12
11ms
In @CD_AACR from @CSHL (Krainer & Tuveson labs) Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated #PancreaticCancer https://t.co/PEmTXSQ2Fd So much interest in non-genomically deregulated splicing factors & aberrant splicing in pancreatic cancer! (@Aiims1742)
11 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12
11ms
Do you have breast cancer G12D KRAS ? (@KRASKickers)
11 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12
12ms
Remarkable data by @udai_banerji and team! Always surprising us with something new! That's one dramatic 🫁 #NSCLC #KRAS G12D response! Added @ASCO (22) avutometinib/ everolimus data for context. Perhaps, combo with PAN-KRASi RMC-6236 (AACR23 data) would be of interest! https://t.co/1TEAbkKWC1 (@CrozrX)
12 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12
|
everolimus • avutometinib (VS-6766) • RMC-6236
almost1year
Challenging of combo in KRAS G12C…andG12D #ELCC2023 @myESMO (@dplanchard)
almost 1 year ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12D • KRAS G12
1year
Targeting the “Undruggable” Driver Protein, KRASG12D, as Potential Therapy in Prostate Cancer https://t.co/b7VO9cXPby (@weldeiry)
1 year ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12
1year
A 12-11 One more trial!! Pan #RAS G12i Ph I/Ib 📌https://t.co/xNGnaEYbli 📌n=141 📌RMC6326 📌For KRAS G12A/G12D/ G12R/ G12S or G12V mutant #CRC & other solid tumors 📌Primary end points: DLT, Safety 📌Trial open in the US https://t.co/2y2vpJDmAH #CRCTrialsChat #CRCSM (@manjuggm)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)
|
KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S
1year
A 12-15 KRAS G12Di Ph I/II multiple expansion cohort 📌https://t.co/DW70Qy5wzJ 📌n=304 📌MRTX 1133 (KRAS G12Di) 📌For KRAS mt #CRC & other solid tumors 📌Primary end points: DLT, Safety, ORR, DOR, PFS, OS 📌KRAS G12D #CRC & others 📌Trial open in the US #CRCTrialsChat @OncoAlert (@manjuggm)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12
|
MRTX1133
1year
A 3-4 📌Among typical RAS mutations, KRAS G12C & G12D mutations have targeted therapy available in #clinicaltrials. 📌This is another reason why knowing your specific RAS mutation is important https://t.co/uiyosHMos8 #CRCTrialsChat #CRCSM #colorectalcancer (@jonathanloree)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12D • RAS mutation • KRAS G12
1year
#ESMOSarcomaandrarecancers23: Database studies in appendix adenocarcinoma suggest that chemo may provide a survival benefit in node-positive tumours and that the KRAS G12D mutation could be a potential therapeutic target 👉 https://t.co/XEL92eBNcx @alarjosan @TheChristieNHS (@myESMO)
1 year ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D • KRAS G12
1year
KRAS G12D inhibitors are on their way… ! Promising preclinical activity, a good news for patients with pancreatic cancer or other KRAS G12Dmut tumors (@mihaela_aldea)
1 year ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D
1year
Multiple orthogonal preclinical models of #PancreaticCancer were used here (human & murine cell lines, organoids, autochthonous models) showing activity of KRASG12D inhibition in advanced disease but remarkably also reversing EARLY precursors. Congratulations to the team! (@Aiims1742)
1 year ago
Preclinical • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D
1year
Multiple orthogonal preclinical models of #PancreaticCancer were used here (human & murine cell lines, organoids, autochthonous models) showing activity of KRASG12D inhibition in advanced disease but remarkably also reversing EARLY precursors. Congratulations to the team! (@Aiims1742)
1 year ago
Preclinical • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D
1year
Preclinical activity of MRTX1133 in #KRAS G12D pancreatic cancer models now @CD_AACR. Deep regressions noted in models but required T-cells (depletion allowed regrowth). Interesting intersection of targeted therapy and IO. KRAS G12D remains major need. https://t.co/U9OWNFfuAc (@StephenVLiu)
1 year ago
Preclinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12
|
MRTX1133
1year
Mirati Therapeutics Inc. - Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133 Hopeful for Pancreatic Cancer https://t.co/ePanuB4WIF (@DanZhaoMD)
1 year ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D
|
MRTX1133
1year
Inhibiting kras G12D led to tumor regression and change in the TME. Implication for combination therapy. @CD_AACR @AndrewMWaters Efficacy of a small molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer https://t.co/1kvrOQx8oK (@SyedAAhmad5)
1 year ago
Clinical • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D
1year
Efficacy of a small molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer https://t.co/HLxNxcKIQa (@VivekSubbiah)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D
1year
Another novel mechanism to directly target mutant KRAS G12D that has entered clinical trials is the @AstellasUS degrader ASP-3082, that is undergoing evaluation in Phase 1 studies (including previously treated #PancreaticCancer) https://t.co/Ont2GvaEcz (@Aiims1742)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D • KRAS G12
|
ASP3082
1year
Very excited about @MDAndersonNews own homegrown effort of genetically targeting mutant KRAS G12D using systemically delivered exosomes (iExosomes) in metastatic #PancreaticCancer. Science emanating from @KalluriLab, trial led by @drsmags @EJShpallMD https://t.co/wCqaXNISv5 (@Aiims1742)
1 year ago
Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D • KRAS G12
1year
Clinical trials of TCR engineered autologous T cells targeting HLA-restricted KRAS neoepitopes (including G12D & G12V) are now ongoing in patients with #PancreaticCancer & other solid cancers. Two examples below: https://t.co/Wty1VFhFzx https://t.co/4y425IGNyH (Specific to G12V). (@Aiims1742)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V • KRAS G12
1year
The scope of direct KRAS targeting in #PancreaticCancer in 2022 extended beyond small molecules. Eric Tran @BernardAFox et al @ChilesResearch demonstrated T cell receptor (TCR) engineered autologous T cells targeted against KRASG12D can elicit responses. https://t.co/4dlfHrDQGD (@Aiims1742)
1 year ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12
over1year
Thanks for posting. Does it say the results for colon cancer with kras g12d? (@pissed_off_mom_)
over 1 year ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12
over1year
Preclinical report of #KRAS G12D inhibitor MRTX1133 @CD_AACR. Efficacy noted in pancreatic models and interesting effect on the tumor microenvironment with this agent. Important target in NSCLC as well and this mutation often occurs in non-smokers. https://t.co/dWQuLpJnYB (@StephenVLiu)
over 1 year ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D
|
MRTX1133
over1year
Data presented by @tajiknia #AACRJCA22 shows MRTX1133 suppression of pERK at nM doses & synergies with 5-FU in CRC & pancreatic cancer cells with #KRAS G12D, G12V, & G13D. More studies needed before excluding non-G12D mutations from trials @BrownUCancer @BrownMedicine #eldeirylab https://t.co/DUlynIqYZH (@weldeiry)
over 1 year ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V • KRAS G12 • KRAS G13
|
5-fluorouracil • MRTX1133
over1year
KRAS mutations occur in >90% of #PancreaticCancer #patients & the G12D variant is most common. In a @AACR @CD_AACR #OpenAccess #researchpaper @sam_kemp20 & team use a G12D specific inhibitor in relevant models of #pancsm ➡️very promising💜 @OncoAlert 🚨 https://t.co/4OLxunSuqq (@BenWestphalen)
over 1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D
over1year
Efficacy of a small molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer | Cancer Discovery | American Association for Cancer Research Looking forward to the KRASG12D inhibitor, MRTX1133, in clinical trials for pancreatic cancer https://t.co/h7paPEYKhr (@DanZhaoMD)
over 1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D
|
MRTX1133
over1year
Efficacy of a small molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer 👀🎯 https://t.co/QjbWOBgEyb (@zpyeung)
over 1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D
over1year
Drugging the undruggable one allele at a time: Now KRAS G12D in pancreatic cancer. FYI one third of >6000 pancreatic patient samples in @AACR #ProjectGENIE are KRAS G12D mutant (@CDebyaniPhD)
over 1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12
over1year
🚨🚨🚨 First preclinical data on @Mirati MRTX1133 (KRAS G12D inh) in #PancreaticCancer models is here in @CD_AACR From @BenStanger01 & colleagues https://t.co/ukuFOpiEN0 Interesting nuanced twist on the question - do the T cells matter in the observed anti tumor response? (@Aiims1742)
over 1 year ago
Preclinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12
|
MRTX1133
over1year
✳️Some of these agents seems to offer highly promising outcomes and provide novel therapeutics for our patients❗️ ✳️Unlike Lung cancer, unfortunately, KRAS G12C are uncommon (~3%) in CRC and KRAS G12D most common mutant (~40%)❗️ (@IbrahimSahinMD1)
over 1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12D • KRAS G12
over1year
Some of the KRAS trials for pancreatic cancer patients referenced by Dr. @EileenMOReilly in #GDUGI2022 Astellas' ASP3082 for G12D https://t.co/INHYrUJ0lG Revolution Medicines RMC-6236 (Pan-RAS inhibitor) https://t.co/fsTDMoArdN @KRASKickers (@fireflyann)
over 1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D
|
ASP3082 • RMC-6236
over1year
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer @Annals_Oncology https://t.co/OcmAWcaOmW (@VivekSubbiah)
over 1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D • KRAS G12
over1year
Here we go……Just out👇🏼👇🏼👇🏼 Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor @NatureMedicine @SWOG @DavendraSohal @Aiims1742 @pashtoonkasi @GIcancerDoc @CathyEngMD https://t.co/ruMa5BZYXC (@SyedAAhmad5)
over 1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D
over1year
Online @NatureMedicine: Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (MRTX1133 from @Mirati, with particular relevance to #PancreaticCancer) https://t.co/ak61d8IJO2 The Research Briefing was out last week so been waiting! https://t.co/wNwJjJusJD (@Aiims1742)
over 1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D
|
MRTX1133
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login